Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fusion MM-005: daratumumab plus durvalumab in daratumumab-refractory relapsed/refractory multiple myeloma
NL-OMON45465Phase 2Withdrawn
- Sponsor
- Celgene Corporation
- Start
- Mar 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab and durvalumab in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Overall response rate. Planned start Mar 2017; status: withdrawn.
02
Drugs
daratumumabdurvalumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON45465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45465.